Global Ocular Drug Delivery Market Overview 2017 - Delivery Technologies, and Partnering Opportunities

Dublin, Aug. 14, 2017 -- The "Ocular Drug Delivery: Market Overview, Delivery Technologies, and Partnering Opportunities" report has been added to Research and Markets' offering.

This page report provides a comprehensive overview of the ocular drug delivery segment and includes detailed product and technology information, market data, DDS pipelines by therapeutic category, company profiles, and partnering opportunities.

It is an exciting time in the field of ocular drug delivery, with a number of innovative delivery systems showing promise. The market is currently dominated by topical products such as drops and ointments which are inefficient and can be difficult tadminister properly. Injectable formulations are available ta lesser extent and can be associated with serious side effects and require administration by a medical professional.

Fortunately there are a record number of companies developing improved ocular delivery systems which provide benefits such as sustained release, accurate dosing, and ease of administration. These companies range from emerging start-ups with preclinical projects to established specialty companies with late-stage pipeline products. Collectively, these companies have more than 70 novel ocular formulations and products in various stages of development for indications such as glaucoma, uveitis, macular degeneration, and dry eye disease.

Report Contents:

• Eye Diseases
• Overview and prevalence data
• Marketed therapeutics by indication
  • Age-related macular degeneration
  • Macular edema
  • Diabetic retinopathy
  • Glaucoma

• Ophthalmic Market Overview
• Sales of top ten ophthalmic products, 2015-2016
• Key players by revenue
• Key players with drug delivery-enabled products
• Ocular Drug Delivery Landscape
• Non-invasive and invasive delivery technologies
• Approved ocular drug delivery formulations
• Ocular drug delivery pipeline by therapeutic category
• Future perspectives and development opportunities
• 46 Company Profiles by Technology Type
• Novel aerosol and eye drop devices
• Punctal plugs
• Topical delivery systems
• Injectables and implants
• Ocular inserts
• Drug-eluting lenses

For each company profiled, the following information is provided:

• Technology Description
• Development Status / Pipeline Products
• Patents and Publications
• Partnership Opportunities
• Business Development & Licensing Contact

Reasons to Buy:

• Identify enabling delivery systems or devices for pipeline drugs
• Scout technologies for life cycle management of commercialized ophthalmic drugs
• Understand the key players and therapeutic segments
• Obtain product and technology information for launched ophthalmics
• View pipeline details for novel ocular formulations in development
• Discover product and technology licensing opportunities

Key Topics Covered:

Chapter I: Eye Diseases

• Age Related Macular Degeneration (AMD)
• Macular Edema and Diabetic Retinopathy
• Glaucoma
• Inflammatory Conditions

Chapter II: Market Overview

• Key Players

Chapter III: Ophthalmic Drug Delivery Landscape

• Non-Invasive Delivery Technologies
• Invasive Delivery Technologies
• Approved Ocular DDS Products
• Ocular DDS Pipeline
• Development Opportunities
• Future Perspectives

Chapter IV: Technology Profiles

• Aciont, Inc.
• Akorn
• Alcon
• Alimera Sciences
• Allergan
• Amorphex Therapeutics
• Apidel SA
• AsclepiX Therapeutics
• Bausch & Lomb
• Bayer
• Bristol-Myers Squibb
• Charlesson
• CIS Pharma
• Clearside Biomedical
• DelSiTech
• Dompe
• Envisia Therapeutics
• EyeCRO, LLC
• EyeGate Pharma
• Eyenovia
• EyeTrans Technologies
• Genentech
• Glaukos Corporation
• Graybug Vision
• IACTA
• Icon Bioscience
• Inmed
• InSite Vision
• Integral Ophthalmics, LLC
• iVeena Delivery Systems
• Kala Pharmaceuticals
• KMG Pharma
• LayerBio Inc.
• Leo Lens Technology, Inc.
• Mati Therapeutics
• Midatech Pharma
• Mystic Pharmaceuticals, Inc.
• Nanomerics
• Nemera
• Neurotech Pharmaceuticals
• Novaliq GmbH
• Novartis
• OcuJect LLC
• Ocular Therapeutix
• Oculis Pharma
• OcuMedic
• Ohr Pharmaceutical
• Ophthotech
• Peregrine Ophthalmic
• Pfizer
• PolyActiva Pty Ltd.
• pSivida Corporation
• Regeneron
• Replenish, Inc.
• Roche
• Rommelag
• RXI Pharma
• Santen SAS
• SciFluor Life Sciences
• Seagull Technologies
• Senju Pharmaceutical
• SpinDrift Therapeutics
• Spinnaker Biosciences
• Sun Ophthalmics
• Sun Pharmaceuticals
• Taiwan Liposome Company Ltd.
• TheraKine Ltd.
• ThromboGenics
• Topivert
• Valeant
• ViSci Ltd.
• Zeteo Biomedical

For more information about this report visit https://www.researchandmarkets.com/research/rh6gt9/ocular_drug

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Transdermal and Transmucosal Drug Delivery, Optical Disorders Drugs